Brief: Algernon Announces 75% Enrollment In Multinational Phase 2B/3 Human Study Of Ifenprodil For Treatment Of Covid-19
02/10/2020 14:06
Oct 2 (Reuters) - Algernon Pharmaceuticals Inc AGN.CD :
* ALGERNON ANNOUNCES 75% ENROLLMENT IN MULTINATIONAL PHASE
2B/3
HUMAN STUDY OF IFENPRODIL FOR TREATMENT OF COVID-19
Source text for Eikon: ID:nGNX7Vf0fJ
Further company coverage: AGN.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grey Matters Health
See all newsBrief: Grey Matters Announces The Closing Of Its Equity And Convertible Debenture Private Placement Totalling CAD $1.12 Million
Brief: Algernon Announces Additional Increase To Private Placement Financing
Brief: Algernon Health Announces Private Placement
Brief: Algernon Announces Closing Of The Private Placement Financing
Brief: Algernon Announces $1 Mln Private Placement